Benitec Biopharma Inc. (BNTC) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$8.80

From 52W high−41.19%

Volume298141.00

Market cap$323.77M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$8.80

From 52W high

−41.19%

Volume

298141.00

Market cap

$323.77M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.9x

P/E (TTM)

—

RSI (14)

45.4

MomentumView details →

1D Return

+10.48%

YTD Return

−34.74%

SummaryUpdated Jun 1, 2026

Benitec Biopharma Inc. (NASDAQ:BNTC) is a development-stage biotechnology company founded in 1995 and headquartered in Hayward, California. The company went public in 2014 and focuses on developing novel genetic medicines using proprietary DNA-directed RNA interference (ddRNAi) technology. As a clinical-stage biotech firm, Benitec has built its pipeline around treating rare genetic diseases and chronic viral infections through innovative gene therapy approaches.

Ask drillr about Benitec Biopharma Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−25.73%

ROA (TTM)

−24.94%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+37.97%

FCF YoY

+28.59%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+6.67%

EBITDA YoY

−13.88%

MomentumView details →

1D Return

+10.48%

YTD Return

−34.74%

1Y Return

−44.30%

RSI (14)

45.4

vs 50D SMA

−13.13%

vs 200D SMA

−23.51%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

34.00x

Quick Ratio

34.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

1.62%

Beats (12Q)

7/12

Next Q EPS Est

−$0.30

Avg Surprise (4Q)

9.21%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−45.55M

Op. CF (TTM)

−16.98M

Next earningsNov 13, 2026 →

Latest newsMore news →

Benitec Biopharma received formal FDA feedback following a Type C meeting regarding an open-label, single-arm pivotal study for BB-301, with the FDA requesting additional available data including data from Benitec's OPMD Natural History Study.31d ago

Similar companies

Prelude Therapeutics IncorporatedPRLD X4 Pharmaceuticals, Inc.XFOR Kyverna Therapeutics, Inc.KYTX Scribe Therapeutics Inc.SCTX Agenus Inc.AGEN AgomAb Therapeutics N.V. American Depositary SharesAGMB Find similar companies →

Latest newsMore news →

Benitec Biopharma announced positive interim Phase 1b/2a clinical results for high-dose BB-301 and continued durable improvements for low-dose BB-301 in patients with OPMD, reporting that all treated patients across both doses were formal responders.8d ago Benitec Biopharma received formal FDA feedback following a Type C meeting regarding an open-label, single-arm pivotal study for BB-301, with the FDA requesting additional available data including data from Benitec's OPMD Natural History Study.31d ago Benitec Biopharma Inc. changed its certifying accountant to Ernst & Young LLP on September 29, 2026.35d ago